Beaver Addresses FDA’s Planned New Guidance for Drug Developers

Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development.

Beaver said the FDA’s planned guidance doubles down on its commitment to partner with companies early and often in the drug development process. “Guidance on best practices and procedures for collaborating during drug development should be welcomed by industry,” he said, adding that FDA Commissioner Scott Gottlieb’s engagement on the issue is encouraging and “demonstrates his continued commitment to working with industry to increase the efficiency of the process.”